Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer

Nature Reviews Urology

Volumn 8, Issue 10, 2011, Pages 569-578

  Pchejetski, Dmitri ^a   Böhler, Torsten ^b   Stebbing, Justin ^a   Waxman, Jonathan ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Research and Development   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; AMINOACYLASE; ATROPINE; CABAZITAXEL; CATENIN DELTA; CD31 ANTIGEN; CYTOCHROME P450; FILAMIN A; FINGOLIMOD; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLSERINE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE C; SHP2 TYROSINE PHOSPHATASE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE TYPE 1 INTERACTING PROTEIN; TAMOXIFEN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; BRADYCARDIA; BREAST CANCER; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ASSESSMENT; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; EDEMA; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROSIS; GLEASON SCORE; GLIOMA; HEAD AND NECK CANCER; HERPES SIMPLEX; HISTOLOGY; HOMEOSTASIS; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; LYMPHOCYTE MIGRATION; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE SCLEROSIS; NEOVASCULARIZATION (PATHOLOGY); NERVE CELL; NOCICEPTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; SALIVARY GLAND CANCER; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CANCER; STOMACH CANCER; TISSUE; TRANSIENT MACULA EDEMA; TREATMENT DURATION; TUMOR XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROPYLENE GLYCOLS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 80054037863     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.117     Document Type: Review

References (166)

1. American Cancer Society. How many men get prostate cancer? [online] http://www.cancer.org/cancer/prostatecancer/overviewguide/prostate-cancer- overview-key-statistics (2011).
2. Cancer Research UK. Prostate cancer statistics-Key Facts http://info.cancerresearchuk.org/cancerstats/keyfacts/prostate-cancer/ (2011).
3. Reynolds, M. A. Molecular alterations in prostate cancer. Cancer Lett. 271, 13-24 (2008).
4. Routh, J. C. & Leibovich, B. C. Adenocarcinoma of the prostate: Epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin. Proc. 80, 899-907 (2005).
5. Nelson, W. G., De Marzo, A. M. & Isaacs, W. B. Prostate cancer. N. Engl. J. Med. 349, 366-381 (2003).
6. Steineck, G. et al. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol. 41, 668-674 (2002).
7. Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520 (2004).
8. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004).
9. Malavaud, B. et al. Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur. J. Cancer 46, 3417-3424 (2010).
10. Pchejetski, D. et al. FTY720 (Fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 70, 8651-8661 (2010).
11. Taha, T. A., Hannun, Y. A. & Obeid, L. M. Sphingosine kinase: Biochemical and cellular regulation and role in disease. J. Biochem. Mol. Biol. 39, 113-131 (2006).
12. Pitson, S. M. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem. Sci. (2010).
13. Mitra, P. et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc. Natl Acad. Sci. USA 103, 16394-16399 (2006).
14. Takabe, K. et al. Estradiol induces export of sphingosine-1-phosphate from breast cancer cells via ABCC1 and ABCG2. J. Biol. Chem. 285, 10477-10486 (2010).
15. Hisano, Y., Kobayashi, N., Kawahara, A., Yamaguchi, A. & Nishi, T. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. J. Biol. Chem. 286, 1758-1766 (2011).
16. Young, N. & Van Brocklyn, J. R. Signal transduction of sphingosine-1-phosphate G protein-coupled receptors. Scientific World Journal 6, 946-966 (2006).
17. Takabe, K., Paugh, S. W., Milstien, S. & Spiegel, S. "Inside-out" signaling of sphingosine-1-phosphate: Therapeutic targets. Pharmacol. Rev. 60, 181-195 (2008).
18. Strub, G. M., Maceyka, M., Hait, N. C., Milstien, S. & Spiegel, S. Extracellular and intracellular actions of sphingosine-1-phosphate. Adv. Exp. Med. Biol. 688, 141-155 (2010).
19. Duan, H. F. et al. Sphingosine kinase activation regulates hepatocyte growth factor induced migration of endothelial cells. Exp. Cell Res. 298, 593-601 (2004).
20. Hait, N. C. et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325, 1254-1257 (2009).
21. Alvarez, S. E. et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465, 1084-1088 (2010).
22. Pitson, S. M. et al. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J. Exp. Med. 201, 49-54 (2005).
23. Xia, P. et al. An oncogenic role of sphingosine kinase. Curr. Biol. 10, 1527-1530 (2000).
24. Olivera, A. et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J. Cell Biol. 147, 545-558 (1999).
25. Xia, P., Wang, L., Gamble, J. R. & Vadas, M. A. Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. J. Biol. Chem. 274, 34499-34505 (1999).
26. Le Scolan, E. et al. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 106, 1808-1816 (2005).
27. Bonhoure, E. et al. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 20, 95-102 (2006).
28. Song, L. et al. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-{kappa}B pathway in human non-small cell lung cancer. Clin. Cancer Res. 17, 1839-1849 (2011).
29. Sukocheva, O. A. et al. Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Mol. Endocrinol. 17, 2002-2012 (2003).
30. Billich, A. et al. Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: Function in cell survival and IL-1beta and TNF-alpha induced production of inflammatory mediators. Cell Signal. 17, 1203-1217 (2005).
31. Bayerl, M. G. et al. Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk. Lymphoma 49, 948-954 (2008).
32. French, K. J. et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 63, 5962-5969 (2003).
33. Licht, T., Tsirulnikov, L., Reuveni, H., Yarnitzky, T. & Ben-Sasson, S. A. Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3). Blood 102, 2099-2107 (2003).
34. Visentin, B. et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9, 225-238 (2006).
35. Akao, Y. et al. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem. Biophys. Res. Commun. 342, 1284-1290 (2006).
36. Pchejetski, D. et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 65, 11667-11675 (2005).
37. Gude, D. R. et al. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal. FASEB J. 22, 2629-2638 (2008).
38. Weigert, A. et al. Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Mol. Biol. Cell 18, 3810-3819 (2007).
39. Johann, A. M. et al. Apoptotic cell-derived sphingosine-1-phosphate promotes HuR-dependent cyclooxygenase-2 mRNA stabilization and protein expression. J. Immunol. 180, 1239-1248 (2008).
40. Xie, B. et al. Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J. Cell Physiol. 218, 192-198 (2009).
41. Doll, F., Pfeilschifter, J. & Huwiler, A. Prolactin upregulates sphingosine kinase-1 expression and activity in the human breast cancer cell line MCF7 and triggers enhanced proliferation and migration. Endocr. Relat. Cancer 14, 325-335 (2007).
42. Kaneider, N. C., Djanani, A., Fischer-Colbrie, R. & Wiedermann, C. J. Sphingosine kinase-dependent directional migration of leukocytes in response to phorbol ester. Biochem. Biophys. Res. Commun. 297, 806-810 (2002).
43. Maceyka, M., Alvarez, S. E., Milstien, S. & Spiegel, S. Filamin A links sphingosine kinase 1 and sphingosine-1-phosphate receptor 1 at lamellipodia to orchestrate cell migration. Mol. Cell Biol. 28, 5687-5697 (2008).
44. Shida, D. et al. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res. 68, 6569-6577 (2008).
45. Hobson, J. P. et al. Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science 291, 1800-1803 (2001).
46. Hla, T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol. Res. 47, 401-407 (2003).
47. Graler, M. H. et al. The sphingosine 1-phosphate receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13. J. Cell Biochem. 89, 507-519 (2003).
48. Maeda, Y. et al. Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J. Immunol. 178, 3437-3446 (2007).
49. Van Brocklyn, J. R., Young, N. & Roof, R. Sphingosine-1-phosphate stimulates motility and invasiveness of human glioblastoma multiforme cells. Cancer Lett. 199, 53-60 (2003).
50. Berdyshev, E. V. et al. Intracellular S1P generation is essential for S1P-induced motility of human lung endothelial cells: Role of sphingosine kinase 1 and S1P lyase. PLoS ONE 6, e16571 (2011).
51. Arikawa, K. et al. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J. Biol. Chem. 278, 32841-32851 (2003).
52. Novgorodov, A. S., El-Alwani, M., Bielawski, J., Obeid, L. M. & Gudz, T. I. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J. 21, 1503-1514 (2007).
53. Hashimoto, M. et al. Sphingosine 1-phosphate potentiates human lung fibroblast chemotaxis through the S1P2 receptor. Am. J. Respir. Cell. Mol. Biol. 39, 356-363 (2008).
54. Bryan, L. et al. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: Implications for invasiveness. Mol. Cancer Res. 6, 1469-1477 (2008).
55. Long, J. S. et al. Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine-1-phosphate in estrogen receptor positive breast cancer cells. Mol. Cell Biol. 30, 3827-3841 (2010).
56. Liu, F. et al. Differential regulation of sphingosine-1-phosphate-and VEGF-induced endothelial cell chemotaxis. Involvement of G(ialpha2)-linked Rho kinase activity. Am. J. Respir. Cell. Mol. Biol. 24, 711-719 (2001).
57. Wu, W., Shu, X., Hovsepyan, H., Mosteller, R. D. & Broek, D. VEGF receptor expression and signaling in human bladder tumors. Oncogene 22, 3361-3370 (2003).
58. Anelli, V., Gault, C. R., Snider, A. J. & Obeid, L. M. Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis in vitro. FASEB J. 24, 2727-2738 (2010).
59. Wang, J. D. et al. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate 40, 50-55 (1999).
60. Nava, V. E. et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res. 60, 4468-4474 (2000).
61. Dayon, A. et al. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PLoS ONE 4, e8048 (2009).
62. Ader, I., Brizuela, L., Bouquerel, P., Malavaud, B. & Cuvillier, O. Sphingosine kinase 1: A new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res. 68, 8635-8642 (2008).
63. Sun, Y., Lin, J., Katz, A. E. & Fisher, P. B. Human prostatic carcinoma oncogene PTI-1 is expressed in human tumor cell lines and prostate carcinoma patient blood samples. Cancer Res. 57, 18-23 (1997).
64. Su, Z., Goldstein, N. I. & Fisher, P. B. Antisense inhibition of the PTI-1 oncogene reverses cancer phenotypes. Proc. Natl Acad. Sci. USA 95, 1764-1769 (1998).
65. Leclercq, T. M., Moretti, P. A. & Pitson, S. M. Guanine nucleotides regulate sphingosine kinase 1 activation by eukaryotic elongation factor 1A and provide a mechanism for eEF1A-associated oncogenesis. Oncogene 30, 372-378 (2011).
66. Edsall, L. C., Van Brocklyn, J. R., Cuvillier, O., Kleuser, B. & Spiegel, S. N. N-Dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: Modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry 37, 12892-12898 (1998).
67. Sweeney, E. A. et al. Sphingosine and its methylated derivative N, N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int. J. Cancer 66, 358-366 (1996).
68. Merrill, A. H. Jr et al. Sphingolipids-the enigmatic lipid class: Biochemistry, physiology, and pathophysiology. Toxicol. Appl. Pharmacol. 142, 208-225 (1997).
69. Kono, K., Sugiura, M. & Kohama, T. Inhibition of recombinant sphingosine kinases by novel inhibitors of microbial origin, F-12509A and B-5354c. J. Antibiot. (Tokyo) 55, 99-103 (2002).
70. Pchejetski, D. et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol. Cancer Ther. 7, 1836-1845 (2008).
71. Vessey, D. A. et al. Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. J. Biochem. Mol. Toxicol. 21, 273-279 (2007).
72. Permpongkosol, S. et al. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: Modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int. J. Cancer 98, 167-172 (2002).
73. Paugh, S. W. et al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 112, 1382-1391 (2008).
74. Sukocheva, O., Wang, L., Verrier, E., Vadas, M. A. & Xia, P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology 150, 4484-4492 (2009).
75. Huwiler, A. et al. Loss of sphingosine kinase-1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage. Br. J. Pharmacol. 162, 532-543 (2011).
76. Sarkar, S. et al. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett. 579, 5313-5317 (2005).
77. Brizuela, L. et al. The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer. FASEB J. 24, 3882-3894 (2010).
78. Sauer, L. et al. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. Int. J. Cancer 125, 2728-2736 (2009).
79. Tonelli, F. et al. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal 22, 1536-1542 (2010).
80. Sharma, A. K. Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247). Expert Opin. Ther. Pat. 21, 807-812 (2011).
81. Chiba, K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol. Ther. 108, 308-319 (2005).
82. Budde, K. et al. FTY720 (fingolimod) in renal transplantation. Clin. Transplant. 20 (Suppl. 17), 17-24 (2006).
83. Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415 (2010).
84. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387-401 (2010).
85. Leroux, M. E. et al. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells. Prostate 67, 1699-1717 (2007).
86. Zhou, C. et al. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett. 233, 36-47 (2006).
87. Chua, C. W. et al. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int. J. Cancer 117, 1039-1048 (2005).
88. Nagahara, Y., Ikekita, M. & Shinomiya, T. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J. Immunol. 165, 3250-3259 (2000).
89. Azuma, H. et al. Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. Anticancer Res. 23, 3183-3193 (2003).
90. LaMontagne, K. et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 66, 221-231 (2006).
91. Payne, S. G. et al. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 109, 1077-1085 (2007).
92. Ushitora, Y. et al. Suppression of hepatocellular carcinoma recurrence after rat liver transplantation by FTY720, a sphingosine-1-phosphate analog. Transplantation 88, 980-986 (2009).
93. Nagaoka, Y., Otsuki, K., Fujita, T. & Uesato, S. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells. Biol. Pharm. Bull. 31, 1177-1181 (2008).
94. Wolf, A. M. et al. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J. Immunol. 183, 3751-3760 (2009).
95. Nishikawa, H. & Sakaguchi, S. Regulatory T cells in tumor immunity. Int. J. Cancer 127, 759-767 (2010).
96. Domhan, S., Zeier, M. & Abdollahi, A. Immunosuppressive therapy and post-transplant malignancy. Nephrol. Dial. Transplant 24, 1097-1103 (2009).
97. Tedesco-Silva, H. et al. FTY720 versus mycophenolate mofetil in de novo renal transplantation: Six-month results of a double-blind study. Transplantation 84, 885-892 (2007).
98. Graler, M. H. Targeting sphingosine 1-phosphate (S1P) levels and S1P receptor functions for therapeutic immune interventions. Cell. Physiol. Biochem. 26, 79-86 (2010).
99. Skerjanec, A. et al. FTY720, a novel immunomodulator in de novo kidney transplant patients: Pharmacokinetics and exposure-response relationship. J. Clin. Pharmacol. 45, 1268-1278 (2005).
100. Kovarik, J. M. et al. Ethnic sensitivity study of fingolimod in white and Asian subjects. Int. J. Clin. Pharmacol. Ther. 45, 98-109 (2007).
101. Kovarik, J. M., Schmouder, R., Barilla, D., Wang, Y. & Kraus, G. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br. J. Clin. Pharmacol. 57, 586-591 (2004).
102. Sensken, S. C., Bode, C. & Graler, M. H. Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy. J. Pharmacol. Exp. Ther. 328, 963-969 (2009).
103. Budde, K. et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13, 1073-1083 (2002).
104. Koyrakh, L., Roman, M. I., Brinkmann, V. & Wickman, K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am. J. Transplant. 5, 529-536 (2005).
105. Kovarik, J. M. et al. Multiple-dose FTY720: Tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J. Clin. Pharmacol. 44, 532-537 (2004).
106. Kovarik, J. M. et al. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. Br. J. Clin. Pharmacol. 66, 199-206 (2008).
107. Schwab, S. R. & Cyster, J. G. Finding a way out: Lymphocyte egress from lymphoid organs. Nat. Immunol. 8, 1295-1301 (2007).
108. Loveridge, C. et al. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J. Biol. Chem. 285, 38841-38852 (2010).
109. Antoon, J. W. et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 151, 5124-5135 (2010).
110. Mizugishi, K. et al. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 25, 11113-11121 (2005).
111. Zemann, B. et al. Normal neutrophil functions in sphingosine kinase type 1 and 2 knockout mice. Immunol. Lett. 109, 56-63 (2007).
112. de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376, 1147-1154 (2010).
113. Pitson, S. M. et al. Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase. J. Biol. Chem. 275, 33945-33950 (2000).
114. Shu, X., Wu, W., Mosteller, R. D. & Broek, D. Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol. Cell Biol. 22, 7758-7768 (2002).
115. Fujita, T. et al. Delta-catenin/NPRAP (neural plakophilin-related armadillo repeat protein) interacts with and activates sphingosine kinase 1. Biochem. J. 382, 717-723 (2004).
116. Xia, P. et al. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. J. Biol. Chem. 277, 7996-8003 (2002).
117. Stahelin, R. V. et al. The mechanism of membrane targeting of human sphingosine kinase 1. J. Biol. Chem. 280, 43030-43038 (2005).
118. Duan, H. F. et al. Shp-2 tyrosine phosphatase is required for hepatocyte growth factor-induced activation of sphingosine kinase and migration in embryonic fibroblasts. Cell Signal. 18, 2049-2055 (2006).
119. Iyer, S. S. & Kusner, D. J. Coordinate regulation of sphingosine kinase and actin dynamics. Methods Mol. Biol. 531, 347-361 (2009).
120. Kusner, D. J. et al. The localization and activity of sphingosine kinase 1 are coordinately regulated with actin cytoskeletal dynamics in macrophages. J. Biol. Chem. 282, 23147-23162 (2007).
121. Hayashi, S. et al. Identification and characterization of RPK118, a novel sphingosine kinase-1-binding protein. J. Biol. Chem. 277, 33319-33324 (2002).
122. Fukuda, Y., Aoyama, Y., Wada, A. & Igarashi, Y. Identification of PECAM-1 association with sphingosine kinase 1 and its regulation by agonist-induced phosphorylation. Biochim. Biophys. Acta 1636, 12-21 (2004).
123. Maceyka, M., Nava, V. E., Milstien, S. & Spiegel, S. Aminoacylase 1 is a sphingosine kinase 1-interacting protein. FEBS Lett. 568, 30-34 (2004).
124. Barr, R. K., Lynn, H. E., Moretti, P. A., Khew-Goodall, Y. & Pitson, S. M. Deactivation of sphingosine kinase 1 by protein phosphatase 2A. J. Biol. Chem. 283, 34994-35002 (2008).
125. Lacana, E., Maceyka, M., Milstien, S. & Spiegel, S. Cloning and characterization of a protein kinase A anchoring protein (AKAP)-related protein that interacts with and regulates sphingosine kinase 1 activity. J. Biol. Chem. 277, 32947-32953 (2002).
126. Kovanich, D. et al. Sphingosine kinase interacting protein is an A-kinase anchoring protein specific for type I cAMP-dependent protein kinase. Chembiochem. 11, 963-971 (2010).
127. Ruckhäberle, E. et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res. Treat. 112, 41-52 (2007).
128. Watson, C. et al. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am. J. Pathol. 177, 2205-2215 (2010).
129. Li, J. et al. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin. Cancer Res. 14, 6996-7003 (2008).
130. Van Brocklyn, J. R. et al. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: Roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J. Neuropathol. Exp. Neurol. 64, 695-705 (2005).
131. Li, W. et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin. Cancer Res. 15, 1393-1399 (2009).
132. Facchinetti, M. M. et al. The expression of sphingosine kinase-1 in head and neck carcinoma. Cells Tissues Organs 192, 314-324 (2010).
133. Sinha, U. K. et al. Increased radiation sensitivity of head and neck squamous cell carcinoma with sphingosine kinase 1 inhibition. Head Neck 33, 178-188 (2010).
134. Liu, G. et al. Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer 10, 495 (2010).
135. Ogretmen, B. & Hannun, Y. A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 4, 604-616 (2004).
136. Fyrst, H. & Saba, J. D. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat. Chem. Biol. 6, 489-497 (2010).
137. Hannun, Y. A. & Obeid, L. M. Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat. Rev. Mol. Cell. Biol. 9, 139-150 (2008).
138. Maceyka, M., Payne, S. G., Milstien, S. & Spiegel, S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim. Biophys. Acta 1585, 193-201 (2002).
139. Pettus, B. J. et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J. 17, 1411-1421 (2003).
140. Cuvillier, O. et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381, 800-803 (1996).
141. Jin, Z. Q., Goetzl, E. J. & Karliner, J. S. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation 110, 1980-1989 (2004).
142. Pchejetski, D. et al. Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ. Res. 100, 41-49 (2007).
143. Gomez-Brouchet, A. et al. Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide. Mol. Pharmacol. 72, 341-349 (2007).
144. Osawa, Y. et al. Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha. J. Biol. Chem. 280, 27879-27887 (2005).
145. Pyne, S., Lee, S. C., Long, J. & Pyne, N. J. Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal. 21, 14-21 (2009).
146. Xia, P. et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc. Natl Acad. Sci. USA 95, 14196-14201 (1998).
147. Radeff-Huang, J., Seasholtz, T. M., Chang, J. W., Smith, J. M. & Walsh, C. T. TNF-alpha -stimulated cell proliferation is mediated through sphingosine kinase-dependent AKT activation and cyclin D expression. J. Biol. Chem. 282, 863-870 (2006).
148. Melendez, A. J. & Ibrahim, F. B. Antisense knockdown of sphingosine kinase 1 in human macrophages inhibits C5a receptor-dependent signal transduction, Ca2+ signals, enzyme release, cytokine production, and chemotaxis. J. Immunol. 173, 1596-1603 (2004).
149. Pchejetski, D. et al. The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4-mediated accumulation of HIF-1alpha protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6. Immunol. Cell Biol. 89, 268-274 (2010).
150. Puneet, P. et al. SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis. Science 328, 1290-1294 (2010).
151. Yamanaka, M. et al. Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation. J. Biol. Chem. 279, 53994-54001 (2004).
152. Cencetti, F., Bernacchioni, C., Nincheri, P., Donati, C. & Bruni, P. Transforming growth factor-beta1 induces transdifferentiation of myoblasts into myofibroblasts via up-regulation of sphingosine kinase-1/S1P3 axis. Mol. Biol. Cell 21, 1111-1124 (2010).
153. Gellings Lowe, N., Swaney, J. S., Moreno, K. M. & Sabbadini, R. A. Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts. Cardiovasc. Res. 82, 303-312 (2009).
154. Serriere-Lanneau, V. et al. The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing. FASEB J. 21, 2005-2013 (2007).
155. Hla, T. & Brinkmann, V. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation. Neurology 76, S3-S8 (2011).
156. Okada, T., Kajimoto, T., Jahangeer, S. & Nakamura, S. Sphingosine kinase/sphingosine 1-phosphate signalling in central nervous system. Cell Signal. 21, 7-13 (2009).
157. Kajimoto, T. et al. Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons. Mol. Cell. Biol. 27, 3429-3440 (2007).
158. Brailoiu, E., Cooper, R. L. & Dun, N. J. Sphingosine 1-phosphate enhances spontaneous transmitter release at the frog neuromuscular junction. Br. J. Pharmacol. 136, 1093-1097 (2002).
159. Pitson, S. M. et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 22, 5491-5500 (2003).
160. Igarashi, N. et al. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J. Biol. Chem. 278, 46832-46839 (2003).
161. Sankala, H. M. et al. Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res. 67, 10466-10474 (2007).
162. Hait, N. C. et al. Role of sphingosine kinase 2 in cell migration toward epidermal growth factor. J. Biol. Chem. 280, 29462-29469 (2005).
163. Weigert, A. et al. Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int. J. Cancer 125, 2114-2121 (2009).
164. Schnitzer, S. E., Weigert, A., Zhou, J. & Brune, B. Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol. Cancer Res. 7, 393-401 (2009).
165. Beljanski, V., Lewis, C. S. & Smith, C. D. Antitumor activity of Sphingosine Kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol. Ther. 11, 524-534 (2011).
166. Antoon, J. W. et al. Targeting NF-kB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol. Ther. 11, 678-689 (2011).